<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875729</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-031-001</org_study_id>
    <nct_id>NCT03875729</nct_id>
  </id_info>
  <brief_title>Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized FcR Non-Binding Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provention Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provention Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether teplizumab slows the loss of β cells and
      preserves β cell function in children and adolescent 8-17 years old who have been diagnosed
      with T1D in the previous 6 weeks..

      Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center
      study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal
      antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1
      diabetes (within 6 weeks of diagnosis). Approximately 300 participants will be randomized at
      a ratio of 2:1 to either the teplizumab group or the placebo group.

      Teplizumab or matching placebo will be administered in two courses 6 months apart. Each
      course of treatment will include daily infusions for 12 days. The total study duration for
      each participant will be up to 86 weeks.

      The primary objective is to determine whether two courses of teplizumab administered 6 months
      apart slows the loss of β cells and preserves β cell function over 18 months (78 weeks) in
      children and adolescents 8-17 years old who have been diagnosed with T1D in the previous 6
      weeks.

      The secondary objectives are to evaluate improvements in key clinical parameters of diabetes
      management, to determine the safety and tolerability of teplizumab, and to evaluate the
      pharmacokinetics (PK) and immunogenicity of teplizumab
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3, randomized, double-blind, placebo-controlled, multinational, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin use</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in glycemic target range</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically important hypoglycemic episodes</measure>
    <time_frame>Week 78</time_frame>
    <description>Clinical Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 52 and Week 78</time_frame>
    <description>Safety Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Teplizumab serum concentrations</measure>
    <time_frame>78 Week</time_frame>
    <description>PK Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers of anti-teplizumab antibodies after treatment courses</measure>
    <time_frame>78 Week</time_frame>
    <description>Immunogenicity Endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>teplizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile solution for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile solution for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>teplizumab</intervention_name>
    <description>Treatment</description>
    <arm_group_label>teplizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study
             drug administration.

          2. Has received a diagnosis of T1D according to the criteria from the American Diabetes
             Association.

          3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the
             formal T1D diagnosis.

          4. Has a peak stimulated C-peptide of ≥0.2 pmol/mL from a mixed meal tolerance test
             (MMTT) at screening.

          5. Has a positive result on testing for T1D-related autoantibodies.

        Exclusion Criteria:

          1. Has any autoimmune disease other than T1D with the exception of stable thyroid or
             celiac disease.

          2. Has an active infection and/or fever.

          3. Has a history of or serologic evidence at screening of current or past infection with
             human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus
             (HCV).

          4. An individual who has a medical, psychological or social condition that, in the
             opinion of the Principal Investigator, would interfere with safe and proper completion
             of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Provention Bio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Provention Bio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>www.theprotectstudy.com</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego (Site 004)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gottschalk, MD</last_name>
      <phone>858-966-8400</phone>
      <email>EndoResearch@rchsd.org.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center (Site 001)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Gitelman, MD</last_name>
      <phone>844-813-8273</phone>
      <email>clinicalresearch@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc. (Site 002)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodalyn Guinto Chuck, MD</last_name>
      <phone>925-930-7267</phone>
      <email>rguinto@diabloclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Albery</last_name>
      <phone>303-724-6766</phone>
      <email>Jennifer.Albery@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University of Medicine (Site 020)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Ryall, RN</last_name>
      <phone>203-737-4510</phone>
      <email>linda.ryall@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UF Clinical and Translation Research Building (Site 015)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haller Michael, MD</last_name>
      <phone>352-273-9294</phone>
      <email>hallermj@peds.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System (Site 028)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Baidal, MD</last_name>
      <phone>305-243-3636</phone>
      <email>sbaidal@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida Diabetes and Endocrinology Center (Site 011)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivette Morales, RN</last_name>
      <phone>813-974-6139</phone>
      <email>imorale4@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates (Site 009)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kioni Smith, RN</last_name>
      <phone>404-355-4393</phone>
      <phone_ext>887</phone_ext>
      <email>KSmith@atlantadiabetes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute (Site 006)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Greene</last_name>
      <phone>706-996-2921</phone>
      <email>jgreene@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center (Site 007)</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Barbieri, MD</last_name>
      <phone>208-522-6005</phone>
      <email>research@idahomed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Site 017)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Phillipson, MD</last_name>
      <phone>773-702-3853</phone>
      <email>ggannon@uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital and Riley Hospital for Children (Site 014)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda DeMeglio, MD</last_name>
      <phone>317-278-8879</phone>
      <email>pedsdiab@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U. Iowa Children's Hospital (Site 023)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Tansey, MD</last_name>
      <phone>866-309-0837</phone>
      <email>pediatric-diabetes-research@uiowa.edu@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital Diabetes &amp; Endocrine Associates (Site 029)</name>
      <address>
        <city>Camp Springs</city>
        <state>Maryland</state>
        <zip>20746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romeu Azevedo, MD</last_name>
      <phone>833-254-6829</phone>
      <email>info@clinvax.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baystate Pediatric Endocrinology &amp; Diabetesl (Site 040)</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ksenia Tonyushkina, MD</last_name>
      <phone>413-794-6690</phone>
      <email>CTO.Staff@baystatehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U. Minnesota Health Clinical Research Unit (Site 031)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoinette Moran, MD</last_name>
      <phone>612-626-8467</phone>
      <email>lesch004@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics (Site 026)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wayne Moore, MD</last_name>
      <phone>816-855-8604</phone>
      <email>wmoore@cmh.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Site 018)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Bollinger</last_name>
      <phone>314-454-4755</phone>
      <email>ashley.bollingher@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo (Site 010)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda House</last_name>
      <phone>716-323-0075</phone>
      <email>ahouse@upa.chob.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Service Northwest, LLC (Site 034)</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Roach</last_name>
      <phone>541-317-5600</phone>
      <email>jsrowach@endonorthwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia - Endocrinology (Site 021)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Willi, MD</last_name>
      <phone>215-590-3668</phone>
      <email>stuartf@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Diabetes and Thyroiid Clinical (Site 013)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Williams, PhD, MD</last_name>
      <phone>605-328-1368</phone>
      <email>DiabetesResearch@sanfordhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center (Site 008)</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesly Draffin, MD</last_name>
      <phone>901-531-6236</phone>
      <email>ljeter@amdiabetes.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (Site 024)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Russell, MD</last_name>
      <phone>615-875-6150</phone>
      <email>faith.brendle@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas (Site 033)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrin White, MD</last_name>
      <phone>214-648-3501</phone>
      <email>perrin.white@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason (Site 016)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Greenbaum, MD</last_name>
      <phone>800-888-4187</phone>
      <email>diabetes@benaroyaresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research &amp; Innovation (Site 003)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Schmitter</last_name>
      <phone>253-403-2699</phone>
      <email>scschmitter@multicare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Diabetes (Site 102)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Elliott, MD</last_name>
      <phone>604-628-7253</phone>
      <email>telliott@bcdiabetes.ca</email>
    </contact>
    <contact_backup>
      <email>minducil@bcdiabetes.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital-McGill (Site 101)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantin Polychronakos, MD</last_name>
      <phone>614-933-0145</phone>
      <email>constantin.polychronakos@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole (Site 301)</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Sumnik, MD</last_name>
      <phone>+420 702 000 087</phone>
      <email>zdenek.sumnik@lfmotol.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s. Masarykova nemocnice v Usti n/ Labem (Site 302)</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Skvor, MD</last_name>
      <phone>+420 477 112 300</phone>
      <email>jaroslav.skvor@kzcr.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus Auf Der Bult (Site 604)</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Kordonouri, MD</last_name>
      <phone>004951181153340</phone>
      <email>kordonouri@hka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem (Site 702)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Luczay, MD</last_name>
      <phone>+3612151380</phone>
      <email>luczay.andrea@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Békés Megyei Központi Kórház Pándy Kálmán Tagkórház ( Site 705)</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katalin H. Nagy, MD</last_name>
      <phone>+3666526526</phone>
      <email>hajdukati.gyk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokor (Site 703)</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iren Kantor, MD</last_name>
      <phone>+36204583828</phone>
      <email>kantoriren@index.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Pomnik - Centrum Zdrowia Dziecka&quot; (Site 801)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miecqyslaw Szalecki, MD</last_name>
      <phone>+48 22 815 77 80</phone>
      <email>mszalecki@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Diabetologii Sp. z o.o. (Site 802)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Pankowska, MD</last_name>
      <phone>+48 22 616 44 74</phone>
      <email>ewa.pankowska@instytutdiabetologii.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne (Site 803)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Mysliwiec, MD</last_name>
      <phone>+48 58 349 28 90</phone>
      <email>malgorzata.mysliwiec@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust Western Bank (Site 903)</name>
      <address>
        <city>Sheffield</city>
        <zip>s10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Wright, MD</last_name>
      <phone>+441142717118</phone>
      <email>n.p.wright@sheffield.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D, type 1 diabetes, recent-onset T1D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

